18F-FDG PET/CT for staging of penile cancer

Journal of Nuclear Medicine

Volumn 46, Issue 9, 2005, Pages 1460-1465

  Scher, Bernhard ^a   Seitz, Michael ^a   Reiser, Martin ^a   Hungerhuber, Edwin ^a   Hahn, Klaus ^a   Tiling, Reinhold ^a   Herzog, Peter ^a   Reiser, Maximilian ^a   Schneede, Peter ^a   Dresel, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

18F FDG; Penile cancer; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; INGUINAL LYMPH NODE; LYMPH NODE METASTASIS; MALE; PENILE BIOPSY; PENIS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UROLOGIC SURGERY; CARCINOMA; CLASSIFICATION; CLINICAL TRIAL; HOSPITALIZATION; IMAGE SUBTRACTION; METASTASIS; METHODOLOGY; MIDDLE AGED; PENIS TUMOR; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PENILE NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 27744519258     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Derakhshani P, Neubauer S, Braun M, Bargmann H, Heidenreich A, Engelmann U. Results and 10-year follow-up in patients with squamous cell carcinoma of the penis. Urol Int. 1999;62:238-244.
2. Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol. 2004;5:240-247.
3. Chen MF, Chen WC, Wu CT, Chuang CK, Ng KF, Chang JT. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J Urol. 2004;22:60-66.
4. Reske SN, Kotzerke J. FDG-PET for clinical use: results of the 3rd German Interdisciplinary Consensus Conference, Onko-PET III, 21 July and 19 September 2000. Eur J Nucl Med. 2001;28:1707-1723.
5. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med. 1995;36:1747-1757.
6. Stahl A, Weber WA, Avril N, Schwaiger M. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin. 2000;39:241-245.
7. Browne JA, De Pierro AR. A row-action alternative to the EM algorithm for maximizing likelihoods in emission tomography. IEEE Trans Med Imaging. 1996;15:687-699.
8. Chiang S, Cardi C, Matej S, et al. Clinical validation of fully 3-D versus 2.5-D RAMLA reconstruction on the Philips-ADAC CPET PET scanner. Nucl Med Commun. 2004;25:1103-1107.
9. Wittekind C, Klimpfinger M, Sobin LH. TNM: Atlas. Berlin, Germany: Springer; 2004:275-282.
10. Solsona E, Iborra I, Rubio J, Casanova JL, Ricos JV, Calabuig C. Prospective validation of the association of local tumor stage and grade as a predictive factor for occult lymph node micrometastasis in patients with penile carcinoma and clinically negative inguinal lymph nodes. J Urol. 2001;165:1506-1509.
11. Syed S, Eng TY, Thomas CR, Thompson IM, Weiss GR. Current issues in the management of advanced squamous cell carcinoma of the penis. Urol Oncol. 2003;21:431-438.
12. Singh I, Khaitan A. Current trends in the management of carcinoma penis: a review. Int Urol Nephrol. 2003;35:215-225.
13. Micali G, Nasca MR, Innocenzi D, Schwartz RA. Invasive penile carcinoma: a review. Dermatol Surg. 2004;30:311-320.
14. Algaba F, Horenblas S, Pizzocaro-Luigi Piva G, et al. EAU guidelines on penile cancer. Eur Urol. 2002;42:199-203.
15. Lont AP, Besnard AP, Gallee MP, van Tinteren H, Horenblas S. A comparison of physical examination and imaging in determining the extent of primary penile carcinoma. BJU Int. 2003;91:493-495.
16. Barone JE, Tucker JB, Perez JM, Odom SR, Ghevariya V. Evidence-based medicine applied to sentinel lymph node biopsy in patients with breast cancer. Am Surg. 2005;71:66-70.
17. Tanis PJ, Lont AP, Meinhardt W, Olmos RA, Nieweg OE, Horenblas S. Dynamic sentinel node biopsy for penile cancer: reliability of a staging technique. J Urol. 2002;168:76-80.
18. Mobilio G, Ficarra V. Genital treatment of penile carcinoma. Curr Opin Urol. 2001;11:299-304.
19. Ell PJ, von Schulthess GK. PET/CT: a new road map. Eur J Nucl Med Mol Imaging. 2002;29:719-720.
20. Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging. 2004;31:932-939.
21. Schoder H, Erdi YE, Larson SM, Yeung HW. PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging. 2003;30:1419-1437.
22. Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004;45(suppl 1):72S-811S.
23. Joerger M, Warzinek T, Klaeser B, Kluckert JT, Schmid HP, Gillessen S. Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology. 2004;63:778-780.
24. Ravizzini GC, Wagner M, Borges-Neto S. Positron emission tomography detection of metastatic penile squamous cell carcinoma. J Urol. 2001;165:1633-1634.
25. 18F-fluoro-L-proline in urologic tumors. J Nucl Med. 2001;42:752-754.
26. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150-185.
27. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837-3844.
28. Rota-Kops E, Krause BJ. Partial volume effects and correction methods. In: Wieler HJ, ed. PET in Clinical Oncology. Darmstadt, Germany: Steinkopff; 1999:35-45.